GlobeNewswire

Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates
05/11/2026
Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre [...]
TerrAscend Reports Third Quarter 2026 Financial Results
05/11/2026
Q3 2026 Net Revenue of $68.2 Million, Up 4.8% Year-Over-Year Q3 2026 Gross Profit Margin of 52.3%, Up 20 Basis Points Year-Over-Year Q3 2026 Net Cash Provided from Continuing Operations of $8.8 Million, Representing 17. [...]
Nephros Announces Strong Third Quarter 2026 Financial Results
05/11/2026
Year Over Year Net Revenue Growth of 18% and Core Programmatic Revenue Growth of 8% for the Three Months Ended September 30, 2026 SOUTH ORANGE, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a [...]
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
05/11/2026
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January [...]
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
05/11/2026
Infection is a Major Unmet Need in Plastic and Reconstructive Surgery: Infection risk was cited in all 11 breast research sessions at the American Society of Plastic Surgeons’ annual meeting, with serious infection [...]
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
05/11/2026
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 QUELL-CV, a Phase 2 [...]
Tarsus to Participate in Upcoming Investor Conferences
05/11/2026
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Guggenheim 3 rd Annual [...]
Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
05/11/2026
Company to host a conference call and audio webcast tomorrow at 8:00 a.m. ET TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company [...]
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 Cash balance of $216.0 million on September 30, 2026, [...]
Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year
05/11/2026
FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora ® Evo system has been named Drug Discovery Innovation of the [...]
Elevar Therapeutics Announces FDA PDUFA Date for Resubmitted New Drug Application for Rivoceranib in Combination With Camrelizumab for Use as a First-line Systemic Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
05/11/2026
FDA assigns a PDUFA target action date of April 9, 2027 Combination achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib’s mOS of 15.2 months FORT LEE [...]
Les données «late-breaking» sur IQIRVO® relèvent les ambitions thérapeutiques dans la CBP : plus de 85 % des patients traités obtiennent une normalisation des PAL
05/11/2026
Les résultats de l’étude ELSPIRE seront présentés en «late-breaking» lors de The Liver Meeting ® 2026 et publiés simultanément dans la revue phare de l’AASLD, HEPATOLOGY À la semaine 52, 85,3 % des patients recevant [...]
IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization
05/11/2026
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting ® 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGY At Week 52, 85.3% of patients receiving IQIRVO ® [...]
RAMSAY SANTE : résultats intermédiaires au 30 septembre 2026
05/11/2026
COMMUNIQUÉ DE PRESSE Paris, 5 novembre 2026 Résultats trimestriels non audités à fin septembre 2026 Ramsay Santé affiche une solide performance au premier trimestre, avec une croissance continue de son chiffre d’ [...]
RAMSAY SANTE : Unaudited interim results at the end of September 2026
05/11/2026
PRESS RELEASE Paris, 5 th November 2026 Unaudited interim results at the end of September 2026 Ramsay Santé delivers solid first-quarter performance, with continued revenue growth and improved operational performance [...]
Significant growth in both revenue and earnings
05/11/2026
ANNOUNCEMENT NR. 325 5 November 2026 Trading statement for Q1 2026/27 (1 July – 30 September 2026) Significant growth in both revenue and earnings Revenue was up by 28% in Q1 2026/27 to DKK 160.0 million from DKK 124.6 [...]
GENFIT : Information financière du troisième trimestre 2026 et point sur les activités de la Société
05/11/2026
La trésorerie et les équivalents de trésorerie s’élèvent à 95,6 millions d’euros au 30 septembre 2026 et permettent un financement des activités au-delà de fin 2028. La croissance attendue des revenus futurs, combinée [...]
GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update
05/11/2026
Cash and cash equivalents of €95.6 million as of September 30, 2026; expected to fund the Company beyond 2028, with continued revenue growth and disciplined spending thereafter expected to drive GENFIT toward [...]
Scipher Medicine and Grupo Amarey Announce First PrismRA® Patient Tests Completed in Colombia
05/11/2026
DURHAM, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scipher Medicine, a leading precision medicine company, today announced that the first patient tests under its strategic partnership with Grupo Amarey have been [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum